SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Dec 15, 2016
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Dec. 15, 2016 · CIK: 0001533040 · Accession: 0001193125-16-794001
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214199
Letter
Re: RXI PHARMACEUTICALS CORPORATION
Acceleration request
Ladenburg Thalmann & Co. Inc.
December 15, 2016
VIA FACSIMILE AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form S-1 (Registration No. 333-214199) -
Concurrence in Acceleration Request
Ladies and Gentlemen:
Ladenburg Thalmann & Co., Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals Corporation that the effective date of the above-referenced registration statement be accelerated to 4:05 p.m. (Eastern Time), or as soon as practicable thereafter, on December 15, 2016, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
LADENBURG THALMANN & CO. INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration request Ladenburg Thalmann & Co. Inc. December 15, 2016 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: RXI PHARMACEUTICALS CORPORATION Registration Statement on Form S-1 (Registration No. 333-214199) - Concurrence in Acceleration Request Ladies and Gentlemen: Ladenburg Thalmann & Co., Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by RXi Pharmaceuticals Corporation that the effective date of the above-referenced registration statement be accelerated to 4:05 p.m. (Eastern Time), or as soon as practicable thereafter, on December 15, 2016, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering. Very truly yours, LADENBURG THALMANN & CO. INC. By: /s/ Nicholas Stergis Name: Nicholas Stergis Title: Managing Director